...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >PI3K and ERK1/2 kinase inhibition potentiate protease inhibitor to attenuate allergen induced Th2 immune response in mouse
【24h】

PI3K and ERK1/2 kinase inhibition potentiate protease inhibitor to attenuate allergen induced Th2 immune response in mouse

机译:PI3K和ERK1 / 2激酶抑制增强蛋白酶抑制剂,以减轻小鼠变应原诱导的Th2免疫应答

获取原文
获取原文并翻译 | 示例

摘要

Proteases affect immune response by activating PI3K, ERK1/2 and p38 kinase. In present study, therapeutic effect of PI3K, ERK1/2 and p38 kinase inhibitor in combination with serine protease inhibitor was evaluated in cockroach extract (CE) induced airway inflammatory disease. Mice were sensitized on day 0, 7 and 14 and challenged on day 27, 28 and 29 with CE. Mice were given PI3K, ERK1/2 and the p38 kinase inhibitor (iPl3K, iERK1/2 and the ip38) alone or with serine protease inhibitor 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), I h before challenge. On day 30 airway resistance of mice were determined and euthanized to collect blood, BAL fluid and lung for analysis. CE immunized mice showed PI3K, ERK1/2 and p38 kinase activation, increased airway resistance, cellular infiltration, Th2 cytokines IgE and IgGl. AEBSF given to mice reduced the CE induced allergic response. AEBSF given in combination of iPl3K/iERK1/2 reduced cellular infiltration in lungs. Furthermore, iPl3K/iERK1/2 with AEBSF significantly reduced the CE induced Th2 cytokines in comparison to monotherapy of kinase inhibitor and AEBSF (P < 0.05). The combination of iPl3K/iERK1/2 with AEBSF enhanced IL -12 level that could further provide a mean of Th2 reduction. Best effect in reduction of allergic response in mice was observed on administration of AEBSF with iPl3K. Conclusively, the combination of PI3K kinase inhibitor with AEBSF reduced allergen induced airway response and has therapeutic potential for add-on therapy in allergic airway disease. (C) 2016 Elsevier B.V. All rights reserved.
机译:蛋白酶通过激活PI3K,ERK1 / 2和p38激酶影响免疫应答。在本研究中,PI3K,ERK1 / 2和p38激酶抑制剂与丝氨酸蛋白酶抑制剂联合在蟑螂提取物(CE)诱发的气道炎性疾病中的治疗效果进行了评估。在第0、7和14天对小鼠进行致敏,并在第27、28和29天用CE攻击。在攻击前1小时,给小鼠单独给予PI3K,ERK1 / 2和p38激酶抑制剂(iPl3K,iERK1 / 2和ip38)或与丝氨酸蛋白酶抑制剂4-(2-氨基乙基)苯磺酰氟盐酸盐(AEBSF)一起使用。在第30天,测定小鼠的气道阻力,并对其进行安乐死以收集血液,BAL液和肺以进行分析。 CE免疫的小鼠显示PI3K,ERK1 / 2和p38激酶激活,气道阻力增加,细胞浸润,Th2细胞因子IgE和IgG1。给予小鼠的AEBSF减少了CE引起的过敏反应。与iPl3K / iERK1 / 2组合使用的AEBSF减少了肺中的细胞浸润。此外,与激酶抑制剂和AEBSF的单一疗法相比,具有AEBSF的iPl3K / iERK1 / 2显着降低了CE诱导的Th2细胞因子(P <0.05)。 iPl3K / iERK1 / 2与AEBSF的结合提高了IL -12水平,可进一步提供Th2降低的平均值。用iPl3K施用AEBSF可以观察到减少小鼠过敏反应的最佳效果。总之,PI3K激酶抑制剂与AEBSF的组合可降低过敏原诱导的气道反应,并具有在过敏性气道疾病中进行附加治疗的治疗潜力。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号